Device for combination therapy. Combination therapy device Combi 400 combination therapy device

COMBI 5-400 machines are designed for complex processing of workpieces from various types of wood and panel materials and perform: longitudinal, transverse, and angled sawing circular saw; plane and edge jointing; thicknessing with automatic feeding blanks; milling surfaces of various shapes; cutting thorns; drilling, slot milling.
The basis of the machine is a rigid frame with high vibration resistance. A movable carriage with a telescopic support moves along a hardened steel guide. Maximum length The cutting width is 1250 mm, and depending on the tasks, the saw unit has an inclination angle from 0° to 45°. The maximum width of jointing and thicknessing is 400 mm, and the thickness of the layer removed in one pass is 3 mm. To select optimal cutting modes, the milling unit has three rotation speeds of 1750/3500/6700 rpm.
The tool guard includes: a rigid casing with a chip reflector and a pipe for chip removal and guide rulers. For operator safety, the machine is equipped with a protective shield that covers the front, protruding part of the tool.

*At your request the machine can be equipped professional tool- both standard and custom.

The machines comply with CE standards.

COMBI 5-400 (BIFFOL, Italy) combined machine,

specifications:

Bronchial asthma: insufficiently controlled by inhaled glucocorticosteroids (GCS) and beta2-agonists short acting as on-demand therapy; adequately controlled by inhaled corticosteroids and long-acting beta2-agonists. Chronic obstructive pulmonary disease (COPD) (with proven effectiveness of the use of GCS).

Contraindications Foradil Combi capsules set with powder for inhalation 400 µg + 12 µg

Hypersensitivity to formoterol or any other component of the drug. Hypersensitivity to budesonide or any other component of the drug. Children's age up to 6 years. Period breastfeeding. For budesonide - active pulmonary tuberculosis. Not recommended for patients with rare hereditary diseases, such as lactase deficiency, lactose intolerance, glucose-galactose malabsorption, since the dosage form contains lactose. Carefully. Formoterol: Extreme caution when using formoterol (especially in terms of dosage regimen) and careful monitoring of the patient is required in the presence of concomitant diseases: ischemic disease hearts; disturbances of heart rhythm and cardiac conduction, especially third degree atrioventricular block; heart disease in the stage of decompensation (including severe chronic heart failure); idiopathic hypertrophic subaortic stenosis; severe arterial hypertension, aortic aneurysm; hypertrophic obstructive cardiomyopathy, thyrotoxicosis; known or suspected QT prolongation (QT corrected > 0.44 sec), hypokalemia, hypocalcemia and pheochromocytoma. Considering the hyperglycemic effect characteristic of beta-agonists, including formoterol, in patients with diabetes mellitus Additional regular monitoring of blood glucose concentrations is recommended. Budesonide: Because budesonide is not effective in relieving acute bronchospasm, the drug should not be used as primary therapy for status asthmaticus or other acute asthmatic conditions. Caution should be exercised when using budesonide in patients with inactive pulmonary tuberculosis, fungal, bacterial and viral infections respiratory tract, liver cirrhosis, glaucoma, hypothyroidism. Also, given the possibility of developing fungal infections, the drug should be used with caution for bronchiectasis and pneumoconiosis. Use during pregnancy and breastfeeding. Formoterol: The safety of formoterol during pregnancy and lactation has not yet been established. The use of the drug during pregnancy is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. Formoterol, like other beta2g-agonists, can inhibit labor due to its tocolytic effect (relaxing effect on the smooth muscles of the uterus). It is not known whether formoterol penetrates into breast milk in humans, in connection with which breastfeeding should be stopped if it is necessary to use the drug in this moment. Budesonide: There are no adequate and well-controlled studies of the use of budesonide in pregnant women. A large epidemiological study of the use of inhaled budesonide during pregnancy revealed no adverse effects on the fetus or newborn. Preclinical studies revealed a possible teratogenic and fetotoxic effect of GCS. Budesonide is excreted into breast milk. The use of the drug during breastfeeding is contraindicated. There is no data on the effect of the drug on fertility. Preclinical studies have shown no effect on fertility with oral formoterol and subcutaneous budesonide.

Method of use and dosage Foradil Combi capsules set with powder for inhalation 400 µg + 12 µg

The drug Foradil Combi is intended for inhalation use in adults and children aged 6 years and older. The drug Foradil Combi are capsules with powder for inhalation, which should be used only with the help of special device- Aerolizer, which is included in the package. The drug is not intended for oral administration. Formoterol and budesonide should be used individually, at the minimum effective dose. When control of bronchial asthma symptoms is achieved during formoterol therapy, it is necessary to consider the possibility of gradually reducing the dose of the drug. Reducing the dose of formoterol is carried out under regular medical supervision. Against the background of exacerbation of bronchial asthma, you should not treat with formoterol or change the dose of the drug. Formoterol should not be used to relieve acute attacks of bronchial asthma. When conducting therapy using an inhalation device, the dose of the drug should be gradually adjusted until a dose sufficient to maintain the therapeutic effect is achieved. Adults: For bronchial asthma, the dose of formoterol for regular maintenance therapy is 12 - 24 mcg (contents of 1-2 capsules) 2 times a day. Formoterol should only be used as adjunctive therapy to inhaled corticosteroids (eg, budesonide). The maximum recommended dose of the drug for adults (48 mcg per day) should not be exceeded. Considering that the maximum daily dose formoterol is 48 mcg; if necessary, an additional 12-24 mcg per day can be used to relieve the symptoms of bronchial asthma. If the need for additional doses of the drug ceases to be episodic (for example, more often than 2 days a week), the patient should consult a doctor to review therapy, as this phenomenon may indicate a worsening of the disease. The minimum dose of budesonide in one capsule is 200 mcg. The drug should not be used if a single dose of less than 200 mcg is required. In adult patients with mild bronchial asthma, treatment begins with a minimum effective dose of 200 mcg/day. The maintenance dose of budesonide for adult patients is 400-800 mcg per day in 2 divided doses (200-400 mcg 2 times a day). In case of exacerbation of bronchial asthma during the transfer of a patient from the use of dosage forms of GCS for oral administration to inhalation forms or when reducing the dose of dosage forms of GCS for oral administration, budesonide should be used at a dose of 1600 mcg/day in 2-4 doses. The dose of the drug is selected individually depending on the needs of the patient. The lowest dose that provides a therapeutic effect should be used. Budesonide should be used daily, on a regular basis. When switching to another inhalation device, the dose of the drug should be re-selected. After each inhalation of budesonide, you should rinse your mouth with water to reduce the risk of developing a fungal infection. Children aged > 6 years. The dose of formoterol for regular maintenance therapy is 12 mcg 2 times a day. The maximum recommended dose of the drug is 24 mcg per day. The drug should not be used to relieve acute attacks of bronchial asthma. To stop an acute attack, it is necessary to use short-acting beta2-adrenergic receptor agonists. Due to the lack of clinical experience in children under 6 years of age, budesonide should not be used in patients of this age group. age group. Treatment in children with mild bronchial asthma should begin with a dose of 200 mcg/day. The dose of budesonide for regular maintenance therapy is 400 mg in 2 divided doses (200 mcg 2 times a day). If necessary, the dose of budesonide can be increased to a maximum of 800 mcg/day. Chronic obstructive pulmonary disease (COPD): The dose of formoterol for regular maintenance therapy is 12-24 mcg (contents of 1-2 capsules) 2 times a day. The maximum recommended dose of the drug for adults (48 mcg per day) should not be exceeded. The maintenance dose of budesonide for adult patients is 400-800 mcg per day in 2 divided doses (200-400 mcg 2 times a day). In case of exacerbation of bronchial asthma during the transfer of a patient from the use of dosage forms of GCS for oral administration to inhalation forms or when reducing the dose of dosage forms of GCS for oral administration, budesonide should be used at a dose of 1600 mcg/day in 2-4 doses. The dose of the drug is selected individually depending on the needs of the patient. The lowest dose that provides a therapeutic effect should be used. Budesonide should be used daily, on a regular basis. When switching to another inhalation device, the dose of the drug should be re-selected. After each inhalation of budesonide, you should rinse your mouth with water to reduce the risk of developing a fungal infection. Patients with impaired renal function. There is no data on the need to adjust the dose of the drug in patients with impaired renal function. Based on the pharmacokinetics of oral budesonide, it is unlikely that systemic exposure to the drug would be clinically significant in these patients. There is no data on the need to adjust the dose of the drug in patients with impaired liver function, however, budesonide is metabolized mainly in the liver. In this regard, the drug should be used with caution in patients with severe liver dysfunction. In patients with mild or moderate hepatic impairment, it is unlikely that the effect of the drug will significantly change, taking into account the pharmacokinetic parameters of budesonide when administered orally. Elderly patients (over 65 years old). There is no data on the need to adjust the dose of the drug in patients over 65 years of age. Instructions for inhalation. To provide correct application drug, the nurse or doctor should teach the patient correct technique using an inhaler; explain that capsules with powder for inhalation should only be used using an Aerolyzer; Warn the patient that the capsules are for inhalation use only and are not intended to be swallowed. In children and adolescents, inhalation of budesonide and formoterol should be carried out under adult supervision. It is necessary to ensure that the child performs the inhalation technique correctly. It is important to warn the patient that if the gelatin capsule ruptures, small pieces of gelatin may enter the mouth or throat as a result of inhalation. In order to minimize this phenomenon, you should not pierce the capsule more than once. The capsule is made of edible gelatin and is not harmful if swallowed. Remove the capsule from the blister pack immediately before use. Rinsing the mouth with water after inhaling budesonide can prevent the development of irritation of the oral and pharyngeal mucosa, and also reduce the risk of developing systemic adverse events. There are isolated reports of accidental swallowing of drug capsules whole. Most of these cases are not associated with the development of adverse events. To the nurse or the doctor should teach the patient the correct technique for using the drug, especially if the patient’s breathing does not improve after inhalation.

Devices for combination therapy of the “400” series have a special software GTS 2, with which you can easily determine the parameters of the most effective therapy to achieve specific medical goals.

Combination therapy device COMBI 400V (Combi 400V): Electrotherapy + vacuum application of electrodes, ultrasound, IR laser.

Device for combination therapy COMBI 400 (Combi 400): Electrotherapy, ultrasound, IR laser. In addition, the Combi 400 device allows you to combine the effects of current, ultrasound and IR laser in any combination.

Peculiarities

Large touch screen control in Russian. No stylus required.

Procedure parameters are set in several ways:

• Through the purpose of treatment.
  The doctor selects the purpose of treatment and localization of the disease on the screen, and the device offers the most effective parameters for the procedure;
• Through a list of 59 indications;
• Through the localization of the disease.
  The doctor selects a treatment zone on the screen, and the device offers a list of diseases associated with the selected zone. The doctor selects a disease, and the device offers procedure parameters for its treatment;
• From freely programmable memory to record 500 of your personal treatment programs;
• Through the therapeutic menu (manual setting of therapy parameters).

253 built-in treatment programs

When selecting specific treatment parameters, the device offers scientifically based treatment recommendations and on-screen explanations of the parameters. For each therapy method, a list of contraindications is displayed on the screen. Schemes of electrode placement for various diseases on the screen.

Electrotherapy (27 types of current)

Programs for supplying several sequential currents.

Special programs for the treatment of pelvic organs with cavity electrodes.

Diagnostic programs (rheobase, chronaxy, accommodation coefficient, S-D curve, pain points).

Vacuum therapy (vacuum application of electrodes)

Vacuum applicators are made of plastic and fit well to convex surfaces. The discharge under the vacuum electrodes was selected to ensure a reliable fit to the surface of the patient’s body and not leave bruises at the application site.

Ultrasound therapy (1 and 3.2 MHz)

Two dual-frequency (1 and 3.2 MHz) waterproof, ergonomic emitters with areas of 4 and 1 cm² are connected to the device simultaneously and are used independently of each other.

The total effective power calculation is displayed on the screen.

Light (on the display and emitter) and sound indication of violation of acoustic contact with stopping the procedure.

Combination therapy

Two independent channels allow you to simultaneously apply two various shapes current, as well as combine electrotherapy, ultrasound therapy and laser therapy in any combination. In the Combi 400V version (COMBI 400V), electrotherapy can be carried out in combination with vacuum effect, which improves blood circulation at the site where the electrodes are applied and enhances the therapeutic effect of the procedure.

Specifications

• Power: 220 V, 50 Hz
• Power consumption: 85 VA
• Protection class II, type BF
• Dimensions (L*W*H): 360 x 260 x 285 mm
• Weight: 5 kg

• Power: 220 V, 50 Hz
• Power consumption: 85 VA
• Protection class II, type BF
• Dimensions (L*W*H): 360 x 260 x 355 mm
• Weight: 7 kg

+
Device for combination therapy Combi 400 V (COMBI 400V)
Electrotherapy + vacuum application of electrodes, UT, IR laser

Device for combination therapy Combi 400 (COMBI 400)
Electrotherapy, ultrasound, IR laser

Devices for combination therapy series "400» have special software GTS 2, which makes it easy to determine the parameters of the most effective therapy to achieve specific medical goals. In addition, the device "Combi 400" allows you to combine the effects of current, ultrasound and IR laser in any combination.

Peculiarities

Large touch screen control in Russian. No stylus required.
Procedure parameters are set in several ways:
- through the purpose of treatment. The doctor selects the purpose of treatment and localization of the disease on the screen, and the device offers the most effective parameters for the procedure;
- through list of 59 indications;
- through the localization of the disease. The doctor selects a treatment zone on the screen, and the device offers a list of diseases associated with the selected zone. Next, the doctor selects a disease, and the device offers procedure parameters for its treatment;
— from freely programmable memory for recording 500 of your personal treatment programs;
- through therapeutic menu (manual setting therapy parameters).

253 built-in treatment programs.

When selecting specific treatment parameters, the device offers scientifically based treatment recommendations and on-screen explanations of the parameters.

FOR each therapy method, a list of contraindications is displayed on the screen.

Schemes of electrode placement for various diseases on the screen.

Electrotherapy ( 31 types of current):

Programs for supplying several sequential currents.
Special programs for the treatment of pelvic organs with cavity electrodes.
Diagnostic programs (rheobase, chronaxy, coefficient of accommodation, S-D curve, pain points). Vacuum therapy (vacuum application of electrodes)

Vacuum applicators are made of plastic and fit well to convex surfaces. The discharge under the vacuum electrodes was selected to ensure a reliable fit to the surface of the patient’s body and not leave bruises at the application site.

Ultrasound therapy (1 and 3.2 MHz)

Two dual frequency (1 and 3.2 MHz) waterproof, ergonomic emitters with areas of 4 and 1 cm 2 are connected to the device simultaneously and are used independently of each other.
The total effective power calculation is displayed on the screen.
Light (on display and emitter) and sound indication of violation of acoustic contact with stopping the procedure.

Combination therapy

Two independent channels allow you to simultaneously apply two different forms of current to the patient, as well as combine electrotherapy, ultrasound therapy and laser therapy in any combination. Available as Combi 400V (COMBI 400V) electrotherapy can be carried out in combination with vacuum exposure, which improves blood circulation at the site of electrode application and enhances the therapeutic effect of the procedure.